Combining CD40 agonist antibodies with immune checkpoint inhibitors enhances anti-tumor effects, suggesting miR-29 may improve immune-based NB therapies by downregulating B7-H3 and activating CD40 [78]. Here, CD40 is linked to neoplasm.